Journal article icon

Journal article

Pramipexole enhances disadvantageous decision-making: Lack of relation to changes in phasic dopamine release

Abstract:

Pramipexole (PPX) is a high-affinity D2-like dopamine receptor agonist, used in the treatment of Parkinson's disease (PD) and restless leg syndrome. Recent evidence indicates that PPX increases the risk of problem gambling and impulse-control disorders in vulnerable patients. Although the molecular bases of these complications remain unclear, several authors have theorized that PPX may increase risk propensity by activating presynaptic dopamine receptors in the mesolimbic system, resulting in...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Experimental Psychology
Role:
Author
ORCID:
0000-0001-9305-1621
More from this funder
Name:
National Institutes of Health
Grant:
R01 DA039687
More from this funder
Name:
University of Kansas Strategic Initiatives
Publisher:
Elsevier
Journal:
Neuropharmacology More from this journal
Volume:
114
Pages:
77-87
Publication date:
2016-11-23
Acceptance date:
2016-11-21
DOI:
EISSN:
1873-7064
ISSN:
0028-3908
Pmid:
27889491
Language:
English
Keywords:
Pubs id:
pubs:713563
UUID:
uuid:e91a8fd9-e421-4901-aec3-dd22af97e718
Local pid:
pubs:713563
Source identifiers:
713563
Deposit date:
2018-09-06

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP